Spear Bio, an innovator in ultrasensitive protein biomarker detection, showcased three new SPEAR UltraDetect™ immunoassays – brain-derived p-Tau 217 (BD-pTau 217), α-synuclein (α-syn) and phospho-Ser129-α-synuclein (pS129-α-syn) – on the Worldwide Convention on Alzheimer’s & Parkinson’s Illnesses (AD/PD 2026) final week. The product debuts coincide with the corporate’s newly established direct-to-customer operations in North America and Europe, an essential step that can streamline entry to its know-how for laboratories investigating neurodegenerative proteinopathies.
The SPEAR UltraDetect BD-pTau 217 Assay, first launched to early adopters final month, stays the one brain-derived pTau 217 check to ship 100 % quantifiability in each wholesome and diseased plasma samples. Working in a homogeneous, wash-free format and requiring simply 1 µL of diluted plasma, the assay achieves a practical decrease restrict of quantification of 25 fg/mL and a mean intra-plate CV of 5.7 %. These attributes permit investigators to detect Alzheimer’s-related tau modifications on the preclinical stage whereas preserving valuable pattern quantity for longitudinal research.
Our purpose is to position essentially the most delicate protein biomarker instruments within the palms of scientists tackling complicated neurodegenerative illnesses, By increasing our assay portfolio and transitioning to direct buyer engagement, we’re empowering researchers to generate higher-quality information with larger effectivity, accelerating the trail from discovery to scientific influence.”
Feng Xuan, Founder and Chief Government Officer, Spear Bio
Complementing the BD-pTau 217 providing, the newly launched α-syn and pS129-α-syn assays deal with crucial wants in Parkinson’s illness and associated synucleinopathies. Each kits quantify monomeric, oligomeric, and post-translationally modified synuclein species at low-femtogram concentrations, with just one µL of diluted pattern, on extensively accessible qPCR devices, eliminating reliance on proprietary readers.
Oliver Tassinari, Vice President of Enterprise Improvement & Technique, underscored the significance of minimal pattern enter. “SPEAR UltraDetect delivers attomolar sensitivity utilizing simply 1 µL of pattern,” Tassinari stated. “For researchers working with valuable biobanked samples, low pattern quantity requirement means richer information from extra assays with out depleting samples.”
Spear Bio was an official sponsor of AD/PD 2026 and offered new validation information in a number of poster periods all through the convention in addition to a product theater on March 21 on the Bella Middle.